Syllabus · Current · V5 (2025) · Cardiovascular System

D7 · Cardiovascular Pharmacology

D7.iii · Antihypertensives

Official V5 objective
Understand the pharmacology of anti-hypertensive drugs.
13 SAQ topics 21 SAQ appearances 10 VIVA stations

Written examination

SAQ history

21 appearances
Outline the pathophysiological basis for the use of angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) in congestive cardiac failure.
Classify calcium channel blockers providing examples (15% marks). Describe the pharmacology of verapamil (85% marks).
35%
Classify calcium channel antagonists and give one example of each class (30% of marks). Describe the pharmacology of Nimodipine including important drug interactions (70% of marks).
19%
Classify calcium channel blockers, and give an example for each classification. (30% of marks) Describe the pharmacology of verapamil. (70% of marks)
61%
Classify the calcium channel blockers and provide one example of a drug for each class (20% marks). Compare and contrast the pharmacology of nimodipine and verapamil (80% marks).
36%
Describe the mechanism of action, dose, pharmacokinetics and pharmacodynamics of clonidine.
38%
List the potential clinical uses of an alpha 2 adrenoceptor agonist. Outline the limitations of clonidine for each use. G
29%
Classify antihypertensive agents by their mechanism of action, with a brief outline of each mechanism, and an example of a drug in each class.
67%
Write short notes on the pharmacology of labetalol and esmolol, highlighting their differences.
32%
List the effects of stimulation of adrenoreceptors on target organs and tissues (60% marks). Describe the mechanism of action and pharmacokinetics of metoprolol (40% marks).
74%
Outline the classification and effects of beta-blocking drugs, including examples (50% marks). Compare and contrast the pharmacokinetics of metoprolol with esmolol (50% marks).
59%
Outline the classification and effects of beta-blocking drugs with examples (50% of marks). Compare and contrast the pharmacokinetics of metoprolol with esmolol (50% of marks).
47%
Compare and contrast metoprolol and verapamil using the following headings: (a) Class and indications for use (20% of marks). (b) Mechanisms of action (25% of marks). (c) Pharmacodynamics and adverse effects (55% of marks).
21%
Describe the pharmacology of Glyceryl trinitrate (GTN).
69%
Define the mechanisms of action and adverse effects of metoprolol and glyceryl trinitrate when used to manage myocardial ischaemia.
80%
Compare and contrast the following pharmacology of sodium nitroprusside and glyceryl trinitrate; (a) mechanism of action (25% of marks) (b) pharmacodynamics and toxicity (75% of marks). Treatment of toxicity is NOT required.
21%
Compare and contrast the mechanisms of action and toxicity of sodium nitroprusside and glyceryl trinitrate (GTN).
55%
Compare and contrast the pharmacology of sodium nitroprusside and glyceryl trinitrate.
Compare and contrast the pharmacology of sodium nitroprusside and glyceryl trinitrate for the treatment of acute hypertension
66%
Describe the pharmacology of intravenous sodium nitroprusside.
49%
Outline the pharmacology of sodium nitroprusside (50% of marks). Discuss the mechanisms of toxicity and their management (50% of marks)
38%

Oral examination

VIVA history

10 stations

Sources: objective text from the relevant CICM syllabus; historical SAQ and VIVA wording from CICM examiner reports.